University of Montana

ScholarWorks at University of Montana
University of Montana News Releases, 1928,
1956-present

University Relations

3-6-1969

Tuberculosis may produce resistance to other diseases
University of Montana--Missoula. Office of University Relations

Follow this and additional works at: https://scholarworks.umt.edu/newsreleases

Let us know how access to this document benefits you.
Recommended Citation
University of Montana--Missoula. Office of University Relations, "Tuberculosis may produce resistance to
other diseases" (1969). University of Montana News Releases, 1928, 1956-present. 4470.
https://scholarworks.umt.edu/newsreleases/4470

This News Article is brought to you for free and open access by the University Relations at ScholarWorks at
University of Montana. It has been accepted for inclusion in University of Montana News Releases, 1928,
1956-present by an authorized administrator of ScholarWorks at University of Montana. For more information,
please contact scholarworks@mso.umt.edu.

netus
Information Services

m issoula, Montana 59801 • (406) 243-2522
yates/bw
3-6-69
state + cs +

IMMEDIATELY

TUBERCULOSIS MAY
PRODUCE RESISTANCE
TO OTHER DISEASES
By Rebecca Yates
UM Information Services
MISSOULA, Mont.-Attempts to eradicate tuberculosis (TB) have produced a startling theory--small amounts
of the disease may be more beneficial than harmful to man.
"We're really excited about this," said Dr. Carl L. Larson, M.D., director of the
Stella Duncan Memorial Institute and professor of microbiology at the University of Montana
in Missoula.
He was referring to research at the institute in which 24 experimental rabbits in
fected with the tubercle bacillus have been studied for resistance to fibromatosis, a
disease marked by the presence of multiple benign tumors.
Dr. Larson and his associates have concluded that rabbits actually infected with
tuberculosis or vaccinated with a live vaccine containing attenuated tubercle bacilli
develop a tremendous resistance to the virus-produced, tumorous disease.
"If everyone were vaccinated with BCG," Dr. Larson speculated, "it might make them
resistant to other diseases," possibly including cancer.
BCG, a vaccine named after French scientist Albert Calmette and surgeon Alphonse
Guerin, introduces an active tubercle bacillus
infection.

into the body, thus immunizing through

Since it is a "live" vaccine it is not widely used in the United States,

although it is used in prevention programs in other countries, Dr. Larson indicated.
more
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Part of the work of the Stella Duncan Memorial Institute, established in 1947 for
the study of allergic diseases, has been to find a "killed" vaccine, a discovery which
was made in 1964, by Dr. Larson and Dr. Edgar Ribi of the Rocky Mountain Laboratory in
Hamilton, Montana.

Another important aspect of the scientists’ work at the institute

has been development of better methods for diagnosis of tuberculosis.
Out of his research, Dr. Larson has developed the theory that controlled infections
with tubercle

bacilli may be a blessing in disguise.

Scientists, he said, are realizing more and more the dangers of tampering with the
natural order and "when you get rid of tuberculosis, you may allow other things to take
place," he added,"things" such as typhoid, influenza and tumorous diseases.
"In 1899," Dr. Larson related, "someone found that if you infected guinea pigs with
tuberculosis and subsequently gave them typhoid fever, they had resistance to the typhoid
bacillus.
"In 1913," he continued, "there was a great outbreak of plague in Manchuria.
vestigators noticed that very few people who died of the plague had tuberculosis.

In
This

was very strange since it was known that there was a lot of active tuberculosis in Manchuria
"Experiments in 1958

at the Pasteur Institute showed that if you gave mice tuberculosi

and then the plague infection, the mice recovered from the plague.

If you give animals

BCG," Dr. Larson said, "they will resist lethal doses of organisms related to the plague
bacilli."
Tuberculosis, or the BCG vaccine, also may immunize against influenza, the doctor
speculated.
"In 1918," he explained, "there was a great epidemic of influenza in this country.
In tuberculosis sanitariums they hardly had any cases of influenza.

You can also instill

resistance to influenza in mice by giving the animals tuberculosis.

Another recent

discovery is that BCG bacilli also are effective in the treatment of leprosy."
more
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In the basement of the Health Sciences Building where the Stella Duncan Institute
houses its experimental animals, Dr. Larson examined a rabbit with its back shaved to show
the ugly, scab-like tumors of fibromatosis.
Moving to a neighboring cage, Dr. Larson took out another rabbit, this one infected
with the same disease but also vaccinated with BCG.

The inflammation of the tumors in the

vaccinated rabbit was much less severe.
Across the hall, a sign on the door warns:

"Danger.

Tuberculosis.

Keep Out."

Donning a mask, Dr. Larson entered the contaminated room and produced a tuberculous
rabbit.

The animal also was infected with fibromatosis but showed remarkably less

evidence of the disease than either of the other two rabbits.
Asked if such experiments with virus-produced tumors might have any relation to
cancer research, Dr. Larson replied, "Yes, we believe many tumors to be virus produced."
Dr. Larson and his associates also are working to perfect the killed vaccine they
discovered some five years ago, capping a search that began in 1955 when Dr. Larson was
working with Dr. Edgar Ribi at the Rocky Mountain Laboratory.
The vaccine is made from an extract of the cell walls of the tubercle bacillus and
the breakthrough in its production came when Dr. Larson was visiting the Pasteur Institute
in Paris for a year.
Dr. Larson and Dr. Ribi had been attempting to break up the cell walls of the tubercul
organism in water but found this water disruption failed to produce an effective immunizing
vaccine.

Researchers in France were using oil in working with the bacilli, but for a

completely different purpose.
Back from Paris, the American scientist attempted a breakup in oil.

This was an

effective but messy process, Dr. Larson related, and later "purely by accident we found out
if you broke these organisms in water, dried the cell walls and then put a drop of oil on
them you formed a sort of paste that was as good as the cell walls broken up in oil."
more
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Test results with the vaccine have been successful, Dr. Larson said.
a resistance in mice which is very good.

"We can produce

Guinea pigs and rabbits are very susceptible to

tuberculosis and the resistance in them is not as good,” he explained.
Rabbits now are being vaccinated at the institute, however, and their rate of
recovery studied.

Dr. Larson produced several lung samples of tuberculous rabbits, plus

those vaccinated with both BCG and the cell-wall vaccine.

The lungs showed that in several

cases the results of the killed vaccine were as good or better than those in the BCG
inoculated rabbits.
Dr. Larson believes the cell-wall vaccine is more effective than BCG and would be of
special benefit in this country, where every year some 50,000 persons still are attacked
by tuberculosis and some 10,000 die from the disease each year.
Dr. Larson also believes a protoplasm by-product of the cell-wall vaccine may be much
more efficient in diagnosis of tuberculosis than the present substance is.

The skin test

now used, the scientist explained, is not specific since the substance, PPD (purified
protein derivative), actually contains 18 different antigens, or antibody producing agents.
Thus, a person showing a positive reaction to the TB test actually may be infected with
organisms other than the tubercle bacillus.
Dr. Larson feels the cell-wall by-product is as good or better than PPD and a
preparation with only one antigen can be produced from the cell-wall material.

Instead of

a general test, diagnosticians might be able to apply five or six tests and if one showed
a positive reaction the specific infecting organism could be detected.
The doctor also believes his substance would be less expensive to produce since it
takes only 10 days to prepare, compared with the several months it takes to make PPD.
The Stella Duncan Memorial Institute was founded through a bequest left by UM alumna
Stella Duncan Johnston, who died of bronchial asthma in 1948.
more
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The work of the institute is carried on with the interest from that bequest plus
continuing grants from the Department of Health, Education and Welfare which over the
past six years have totaled approximately $500,000.
In addition, Dr. Larson received a National Institutes of Health (NIH) Career
Research Award for his salary to do research on resistance to tuberculosis and related
diseases.

One of only some 35 persons in this country to receive one of these life-time

awards, Dr. Larson was the last recipient before the program was canceled.
Dr. Larson was born in Butte, Montana in 1909.

He received his medical degree from

the University of Minnesota in 1939 and holds an honorary doctor of science degree from
the University of Montana.
He began his career with the NIH in 1939 as assistant chief of the Laboratory of
Infectious Diseases at Bethesda, Md., and directed the Rocky Mountain Laboratory from
January 1950 to October 1961.

He became director of the Stella Duncan Memorial

in October 1962.
— rly--
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